Jpmorgan Chase & CO Axcella Health Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.22 - $0.46 $1,208 - $2,525	-5,491 Reduced 99.82%	10 $0
Q1 2023 May 11, 2023	BUY	$0.31 - $0.77 $1,629 - $4,048	5,258 Added 2163.79%	5,501 $2,000
Q4 2022 Feb 13, 2023	BUY	$0.16 - $1.1 $5 - $39	36 Added 17.39%	243 $0
Q3 2021 Nov 12, 2021	BUY	$2.98 - $4.31 $616 - $892	207 New	207 $1,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.